OncoSynergy announced that it has submitted an FDA application for a first-in-human trial of its Orphan Drug designated experimental therapeutic OS2966 for malignant brain cancer. Read press release > click here

San Francisco, California (PRWEB) May 04, 2018 OncoSynergy, an oncology therapeutics spinout from UCSF and current resident of the prestigious JLABS South San Francisco incubator, announced that it has closed a…

South San Francisco, California – June 20, 2017 – Infuseon Therapeutics and OncoSynergy have entered into a strategic alliance to test an investigational glioblastoma therapeutic, OS2966, in combination with a…

San Francisco, California – May 10, 2016 – OncoSynergy, Inc., a biopharma company developing a novel class of therapies for oncology, Resistance Mechanism Inhibitors (RMIs), announced today that it has…

San Francisco, California – (January 20, 2015) OncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for OS2966 in the treatment of…

SAN FRANCISCO, Aug. 12, 2014 /PRNewswire-iReach/ -- OncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing…

OncoSynergy and our lead therapeutic program, OS2966, were featured in an 'Emerging Company Profile' in BioCentury, The Bernstein Report on BioBusiness. See pdf 061614_ECP_OncoSynergy The Bernstein Report is the flagship weekly…

OncoSynergy and CMC Biologics enter into agreement to develop and manufacture material for IND enabling studies and phase I clinical trials. This work will advance OncoSynergy's OS2966 monoclonal antibody drug…

OncoSynergy collaborator, Manish K. Aghi, MD, PhD, Associate Professor of Neurosurgery at University of California at San Francisco, was awarded the Young Investigator Award for Basic/Translational Research at the 4th…

OncoSynergy highlighted in Startup Portraits feature of services provider, Science Exchange. Science Exchange is an online marketplace for outsourcing science experiments. OncoSynergy uses this platform extensively to dramatically increase our research…

Martin Karplus, a co-inventor of key OncoSynergy technologies, awarded the 2013 Nobel Prize in chemistry. Professor Karplus is the Theodore William Richards Professor of Chemistry Emeritus at Harvard and Visiting…